Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death ...

Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Invivyd Inc (NASDAQ:IVVD) stands against the ...

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

H.C. Wainwright reaffirmed its Buy rating and $10.00 price target for Invivyd Inc. (NASDAQ:IVVD), following a series of positive developments for the biotechnology company. The stock, currently ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day’s high of $1.11 ...

Link Parks Inc. Dep. Pfd. (Rep. 1/1000th 5.25% Cum. Redeem. Pfd. Series X)-0.68% Link Parks Inc. Dep. Pfd. (Rep. 1/1000th Share 4.875% Pfd. Series Z) 0.08% Link Parks ...

Kimco Realty Corp. Dep. Pfd. (Rep. 1/1000th 5.25% Cum. Redeem. Pfd. Series M) 0.14% Kimco Realty Corp. Dep. Pfd. (Rep. 1/1000th Pfd. Cl L) 0.00% Federal Realty Investment Trust Dep. Pfd. (Rep. 1 ...

There is currently one antibody available for PrEP in COVID-19 – Invivyd’s Pemgarda (pemivibart) – which was granted Emergency Use Authorization (EUA) in the US in March for adults and ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.